Brambilla C, De Lena M, Rossi A, Valagussa P, Bonadonna G
Br Med J. 1976 Apr 3;1(6013):801-4. doi: 10.1136/bmj.1.6013.801.
A prospective study with two cytotoxic combinations (cyclophosphamide, methotrexate, and fluorouracil (CMF), and adriamycin plus vincristine (AV)) was carried out in 110 patients with advanced breast cancer. There was no significant difference between the treatment groups in the response rate after primary treatment, the median duration of response, and the median survival. In both groups responders survived for longer than non-responders. Secondary treatment after crossover for progression or relapse resulted in response rates of 35% for AV and 20% for CMF. Toxicity was mainly represented by reversible haemosuppression. These results are comparable with those obtained with other multiple-drug regimens, and combination chemotherapy alone seems to have reached a plateau in its capacity to control disseminated breast cancer.
对110例晚期乳腺癌患者进行了一项前瞻性研究，采用两种细胞毒性联合方案（环磷酰胺、甲氨蝶呤和氟尿嘧啶（CMF），以及阿霉素加长春新碱（AV））。在主要治疗后的缓解率、中位缓解持续时间和中位生存期方面，治疗组之间没有显著差异。两组中，缓解者的生存期均长于未缓解者。进展或复发后交叉进行的二线治疗中，AV组的缓解率为35%，CMF组为20%。毒性主要表现为可逆性血液抑制。这些结果与其他多药方案所获得的结果相当，单纯联合化疗在控制播散性乳腺癌的能力方面似乎已达到平台期。
